Tuesday, July 14, 2015

Masimo extended its $ 1,000,000 guarantee performance, according to which the … – Finanzen.net

       Masimo (NASDAQ: MASI), the inventor of Measure-Through Motion and Low
       Perfusion ™ for pulse oximetry, today announced its US $ 1,000,000
       Extended performance guarantee, which pulse oximetry with Masimo SET ®
       All Pulse Oximeter Nellcor (part of Covidien, Medtronic now)
       will surpass. The guarantee states in the event that with Masimo SET
       proven not better performance
       can be provided, as with any of Nellcor pulse oximeter
       including the three for which Covidien obtaining a
       FDA 510 (k) clearance has reported with motion claims, Masimo up to
       Will pay $ 1,000,000 to enable a clinic this pulse oximetry
       can acquire.

       "As a medical technology company we have in our opinion the
       Duty honestly and openly to advertise because it is ultimately for the welfare of the
       Patient goes. We are still confused by the misleading
       Marketing strategy of our competitor, "said Joe Kiani, founder
       and CEO of Masimo. "We are troubled, out the customers astray
       be, and hope that they, inspired by our guarantee in question
       ask what is told them there, and the performance of
       Check technologies itself and evaluate. "

       Apart from the extension of the one-million-dollar guarantee Masimo has its
       Website updated. The company here in detail on each of the
       inaccurate and misleading assertions a: http://www.masimo.com/nellcorfiction/

       Masimo gives each clinic four promises that Covidien has not to
       give was ready:

  1.          We are the superior performance of Masimo SET pulse oximetry with ®
             prove in direct comparison with Nellcor.


  3.          We are independent and objective scientific evidence of
             Provide superiority of Masimo SET ® against Nellcor,
             and evidence that Masimo SET ® clinician in
             Support improving their clinical and financial results.


  5.          We speak very scientific direct comparisons of
             Pulse Oximetry Masimo SET ® with the Nellcor under
             demanding conditions of automatic data capture.


  7.          We are very confident that an objective comparison
             clinical superiority of Masimo SET ® will show and
             continue to provide a performance guarantee in the amount of
             1,000,000 US dollars.


       Please note: This offer is only for hospitals that plan their
       Pulse oximetry hospital campus to bring up to date standard. Important
       Details, terms and conditions for the competition can be found
       under http://www.masimo.com/1millionrules.htm.

 MasimoInnovates | #Masimo

  About Masimo
Masimo (NASDAQ: MASI) is the international
       Leader in innovative, non-invasive
       Monitoring technologies to patient care significantly
       is improved, to help solve "unsolvable" problems. In
       1995, the company debuted Measure-Through-Motion the
       and Low-Perfusion pulse oximetry before, known as Masimo SET®, with the
       False alarms virtually no longer occur. The possibilities
       Pulse oximetry, clinicians in the discovery of life-threatening events
       support, were expanded so. In 2005, Masimo introduced the
       Technology rainbow ® Pulse CO-Oximetry ™ out. This was a
       non-invasive, continuous monitoring of components of blood
       possible what previously required invasive procedures:
       Hemoglobin content (SpHb®), oxygen content (SPOC ™), carboxyhemoglobin
       (SpCO®), methemoglobin (SpMet®), PVI®, and perfusion index (PI), and
       Measurement of motion with SpO2 and pulse rate. In 2008 presented
       Masimo Patient SafetyNet ™, the front, a wireless
       Notification system for remote monitoring for clinicians. Clinics
       are thus able to avoid preventable deaths and injuries,
       such as may occur as a result of failed bailouts. In The
       2009 Masimo introduced before the rainbow® Acoustic Monitoring ™, the
       world's first commercially available technology for non-invasive
       and continuous monitoring of acoustic respiration rate (RRa ™). The
       Founded in 1989, Masimo follows his mission "Improving
       Patient Outcome and Reducing Cost of Care ... by Taking Noninvasive
       Monitoring to New Sites and Applications® "(" improving
       Quality of life and reduction of maintenance costs - by
       Enabling new locations and applications for non-invasive
       Monitoring "). Additional information about Masimo and its products
       see www.masimo.com.

  Forward-Looking Statements This release contains

       "Forward-looking statements" within the meaning of Section 27A of the Securities
       Act of 1933, Section 21E of the Securities Exchange Act of 1934 and
       within the meaning of the Private Securities Litigation Reform Act of 1995. These
       forward-looking statements are based on current expectations about
       future, relevant for our events, and are subject
       Risks and uncertainties that are difficult to make predictions about the
       and many of which are beyond our control. The
       Actual results could therefore result of various risk factors
       related MightySat significantly and in a negative way by the
       differ in our forward-looking statements. These include
       our belief in the groundbreaking potential of Masimo
       SET® pulse oximetry for measurement during motion and low perfusion,
       and other factors discussed in the section entitled "Risk Factors" of the current
       filed by us with the Securities and Exchange Commission ("SEC")
       Reports are described. These are available for free on the site
       the SEC at www.sec.gov.
       Although we believe that our forward-looking statements
       reproduced expectations are realistic, we do not know whether
       our expectations will prove correct. All in
       these statements contained in this press release are in their entirety
       expressly qualified by the previous warnings. They
       are asked not to place undue reliance on these forward-looking
       To leave statements, which only apply to the present time. We
       assume no obligation to update these statements or in our
       contained in the most recent reports filed SEC
       To update, revise or explain in more detail the "Risk Factors"
       - Whether because of new information, future events or otherwise
       Reasons except where it according to applicable securities laws
       is prescribed.

  Masimo, SET, Signal Extraction Technology, Improving Patient Outcome
       and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites
       and Applications, rainbow, SpHb, SPOC, SpCO, SpMet, PVI are
       Trademarks or registered trademarks of Masimo Corporation.


       The initial language in which the original text is published is,
       the official, authoritative version. Translations are for
       better understanding included. Only the language version that the
       Original was published, is legally valid. Straighten therefore
       Translations from the original language of publication.

<- sh_cad_12 ->


No comments:

Post a Comment